KMKazuya Miyagi

Kazuya Miyagi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kazuya Miyagi has a total of 37 co-authors. Here are the top co-authors by number of shared publications:

  • Jiro Fujita

    Respiratory Medicine, Ohama Dai-ichi Hospital, Japan

    6 shared publications
  • Masao Tateyama

    Division of Control and Prevention of Infectious Diseases, Graduate School of Medicine, University of the Ryukyus, 207 Uehara, Nishihara, Okinawa 903-0215, Japan

    5 shared publications
  • Takeshi Kinjo

    First Department of Internal Medicine, Division of Infectious, Respiratory, and Digestive Medicine, University of the Ryukyus Graduate School of Medicine, Okinawa, Japan

    4 shared publications
  • Masashi Nakamatsu

    University of the Ryukyus Hospital, Infection Control Team, Okinawa, Japan

    3 shared publications
  • Futoshi Higa

    Department of Infectious, Respiratory, and Digestive Medicine, Control and Prevention of Infectious Diseases (The First Department of Internal Medicine), Faculty of Medicine, University of the Ryukyus, Japan

    2 shared publications
  • Hideta Nakamura

    First Department of Internal Medicine, Division of Infectious, Respiratory, and Digestive Medicine University of the Ryukyus Graduate School of Medicine Okinawa Japan

    2 shared publications

Latest Publications

  • Open Access

    Efficacy and safety of early administration of remdesivir in hemodialysis patients with COVID-19: A case report and literature review

    by Nanako Oshiro, Takeshi Kinjo, Daigo Aharen, Yuki Kudo, Eisuke Katsuren, Kumiko Omine, Takuto Nakamura, Ryo Zamami, Akio Ishida, Kazuya Miyagi, et al.

    Rationale: Although the mortality of severe coronavirus disease 2019 (COVID-19) has decreased after the emergence of the Omicron variant, it remains high in patients on hemodialysis (HD). Remdesivir (RDV) is considered as the first line drug for hospitalized COVID-19 patients, however the evidence regarding the usage in HD patients is lacking because clinical trials of RDV have excluded HD patients for safety reasons. Thus, accumulation of knowledge on the regimen, efficacy, and tolerability of RDV in HD patients is important. Patient concerns: A nosocomial COVID-19 cluster was occurred from August 31 to October 12 in 2021 when the Delta variant was predominant. During the cluster, 11 health-care workers and 20 inpatients including 7 HD patients were infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Diagnoses: The diagnosis of COVID-19 was confirmed by the real-time polymerase chain reaction (PCR) for SARS-CoV-2. Interventions: RDV was initiated within 16 hours after the onset of fever (≥ 37.4°C) or positive PCR result in all HD patients, and continued at 100 mg/day intravenously once daily for either consecutive 5 or 10 days. Outcomes: All patients fully recovered within 2 weeks and did not develop severe COVID-19. Two patients experienced mild liver dysfunction, but it was temporary and remitted spontaneously even continuing RDV treatment. Discontinuation of RDV therapy due to adverse events was not required in any patients. Lessons: Present cases indicated early intervention with RDV may contribute the favorable outcome and daily administration of RDV for up to 10 days was well tolerated even in HD patients. Literature review showed no previous article reported the efficacy and safety of such earlier and longer administration of remdesivir as in the present cases, therefore this report is informative for clinicians to consider the usage of RDV in HD patients.


  • Open Access

    Case Report: Ischemic Enterocolitis Associated with Coronavirus Disease 2019: Two Case Reports and a Review of the Literature

    by Takeshi Kinjo, Akira Hokama, Hideta Nakamura, Kazuya Miyagi, Yuri Higure, Mariko Otsuki, Naoya Nishiyama, Masashi Nakamatsu, Tetsu Kinjo, Masao Tateyama, et al.

    The COVID-19 pandemic has caused serious health and social concerns worldwide. Although the primary target of SARS-CoV-2 is the respiratory tract, SARS-CoV-2 infection also causes extrapulmonary symptoms. Previous articles have reported ischemic colitis in COVID-19 patients; however, information regarding its clinical manifestations and pathophysiology is limited. In this case report, we present two cases of ischemic enterocolitis in COVID-19 patients and review past case reports. Our literature review has shown that computed tomography rather than endoscopy was used for the diagnosis, and any region of the intestine was affected. Because the elevation of the D-dimer, which suggested a hypercoagulable state, was reported in most cases, we assumed that thrombosis at any level in the artery and vein was involved in the pathophysiology of COVID-19–associated enterocolitis. SARS-CoV-2–induced endotheliitis can cause both coarctation of the vessels and thrombosis; therefore, both patterns of ischemic colitis, occlusive and nonocclusive, may be involved in COVID-19–associated enterocolitis.


  • Open Access

    Case Report: Iliopsoas Hematoma during the Clinical Course of Severe COVID-19 in Two Male Patients

    by Hideta Nakamura, Gen Ouchi, Kazuya Miyagi, Yuuri Higure, Mariko Otsuki, Naoya Nishiyama, Takeshi Kinjo, Masashi Nakamatsu, Masao Tateyama, Ichiro Kukita, et al.

    Anticoagulation plays a major role in reducing the risk of systematic thrombosis in patients with severe COVID-19. Serious hemorrhagic complications, such as intracranial hemorrhage, have also been recognized. However, intra-abdominal hemorrhage is under-recognized because of its rare occurrence, despite high mortality. Here, we discuss two cases of spontaneous iliopsoas hematoma (IPH) likely caused by anticoagulants during the clinical course of COVID-19. We also explored published case reports to identify clinical characteristics of IPH in COVID-19 patients. The use of anticoagulants may increase the risk of lethal IPH among COVID-19 patients becsuse of scarce data on optimal dosage and adequate monitoring of anticoagulant effects. Rapid diagnosis and timely intervention are crucial to ensure good patient outcomes.


  • An Autopsy Case of Two Distinct, Acquired Drug Resistance Mechanisms in Epidermal Growth Factor Receptor-mutant Lung Adenocarcinoma: Small Cell Carcinoma Transformation and Epidermal Growth Factor Receptor T790M Mutation

    by Makoto Furugen, Kayoko Uechi, Jun Hirai, Hajime Aoyama, Masanao Saio, Naoki Yoshimi, Takeshi Kinjo, Kazuya Miyagi, Shusaku Haranaga, Futoshi Higa, et al.

    We herein describe the case of a 63-year-old man who died from relapsed epidermal growth factor receptor gene (EGFR) exon 19 deletion lung adenocarcinoma treated with erlotinib. According to the autopsy results, he was confirmed to have small cell carcinoma without the EGFR T790M mutation in his pancreas and left kidney metastatic specimens, while the adenocarcinoma metastatic lesion in his right kidney had the EGFR T790M mutation; both retained the somatic EGFR exon 19 deletion. We herein report an autopsy case of resistance to an EGFR tyrosine kinase inhibitor via small cell carcinoma transformation and the EGFRT790M mutation in separate metastatic organs.


  • Implementation of bronchoalveolar lavage using a high-flow nasal cannula in five cases of acute respiratory failure

    by Kazuya Miyagi, Shusaku Haranaga, Futoshi Higa, Masao Tateyama, Jiro Fujita


    • 1 November 2013
      • Vol. 88  (11) , 735-8

    [A case of pleural tuberculoma with new pulmonary infiltration during anti-tuberculosis therapy].

    by Shusaku Haranaga, Jun Hirai, Futoshi Higa, Kazuya Miyagi, Eriko Astumi, Masao Tateyama, Jiro Fujita

    A 61-year-old woman who had received treatment for tuberculous pleurisy for 2 months visited our outpatient clinic. Chest computed tomography (CT) showed the presence of a lens-shaped pleural mass with pulmonary infiltration, despite the decreased pleural effusion. Two weeks later, chest CT showed an increase in the size of the mass and expansion of the intrapulmonary shadow. Percutaneous CT-guided lung biopsy was performed, and histopathological examination revealed granulomatous inflammation without caseous necrosis or acid-fast bacilli. Sputum culture was negative for acid-fast bacilli. Anti-tuberculosis medication was continued, and the lesions eventually resolved. These lesions were diagnosed as pleural tuberculomas, and the intrapulmonary infiltration was considered to be due to the paradoxical worsening of the patient's condition.